Clinical Trials · NCT01546987
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Radiation Therapy Oncology Group
- Enrollment
- 239
- Start date
- May 2012
- Locations
- 172 sites, United States, Canada
- Primary endpoint
- Percentage of Participants With Biochemical Failure (Primary Endpoint of Revised Protocol)